Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

The Lancet

Volumn 388, Issue 10062, 2016, Pages 2895-2903

  Teerlink, John R ^a,b   Felker, G Michael ^c   McMurray, John J V ^d   Solomon, Scott D ^e   Adams, Kirkwood F ^f   Cleland, John G F ^g,h   Ezekowitz, Justin A ⁱ   Goudev, Assen ^j   Macdonald, Peter ^k   Metra, Marco ^l   Mitrovic, Veselin ^m,n   Ponikowski, Piotr ^o   Serpytis, Pranas ^p   Spinar, Jindrich ^q   Tomcsányi, János ^r   Vandekerckhove, Hans J ^s   Voors, Adriaan A ^t   Monsalvo, Maria Laura ^u   Johnston, James ^u   Malik, Fady I ^v   Honarpour, Narimon ^u   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY OF BRESCIA   (Italy)

^m KERCKHOFF HEART CENTER   (Germany)

ⁿ GOETHE UNIVERSITY   (Germany)

^o WROCLAW MEDICAL UNIVERSITY   (Poland)

^p VILNIUS UNIVERSITY   (Lithuania)

^q MASARYK UNIVERSITY   (Czech Republic)

^r AZ St Lucas ^*  (Hungary)

^s University Medical Centre Groningen ^*  (Belgium)

^t UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^u AMGEN INC   (United States)

^v Cytokinetics Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARDIAC MYOSIN; OMECAMTIV MECARBIL; PLACEBO; TROPONIN I; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UREA;

ACUTE HEART FAILURE; ADULT; ANGINA PECTORIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE TITRATION; FEMALE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; SYSTOLE; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; CARDIAC MYOSINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; STROKE VOLUME; SYSTOLE; UREA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85003530432     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32049-9     Document Type: Article

References (23)

1. 1 Braunwald, E, Ross, J Jr, Sonnenblick, EH, Mechanisms of contraction of the normal and failing heart. N Engl J Med 277 (1967), 1012–1022.
2. 2 Packer, M, The search for the ideal positive inotropic agent. N Engl J Med 329 (1993), 201–202.
3. 3 Hasenfuss, G, Teerlink, JR, Cardiac inotropes: current agents and future directions. Eur Heart J 32 (2011), 1838–1845.
4. 4 Malik, FI, Hartman, JJ, Elias, KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331 (2011), 1439–1443.
5. 5 Shen, YT, Malik, FI, Zhao, X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 3 (2010), 522–527.
6. 6 Teerlink, JR, Clarke, CP, Saikali, KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378 (2011), 667–675.
7. 7 Cleland, JG, Teerlink, JR, Senior, R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378 (2011), 676–683.
8. 8 Teerlink, JR, Felker, GM, McMurray, JJV, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC AHF study. J Am Coll Cardiol 67 (2016), 1444–1455.
9. 9 Apple, FS, A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 55 (2009), 1303–1306.
10. 10 Thygesen, K, Alpert, JS, Jaffe, AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 60 (2012), 1581–1598.
11. 11 Palaparthy, R, Banfield, C, Alvarez, P, et al. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther 54 (2016), 217–227.
12. 12 Vu, T, Ma, P, Xiao, JJ, Wang, YM, Malik, FI, Chow, AT, Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol 55 (2015), 1236–1247.
13. 13 Greenberg, BH, Chou, W, Saikali, KG, et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail 3 (2015), 22–29.
14. 14 Weissler, AM, Harris, WS, Schoenfeld, CD, Systolic time intervals in heart failure in man. Circulation 37 (1968), 149–159.
15. 15 Biering-Sørensen, T, Roca, GQ, et al. Systolic ejection time is an independent predictor of incident heart failure in a community based cohort free of heart failure. J Card Fail, 21, 2015, S84.
16. 16 Kramer, DG, Trikalinos, TA, Kent, DM, Antonopoulos, GV, Konstam, MA, Udelson, JE, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 56 (2010), 392–406.
17. 17 Solomon, SD, Foster, E, Bourgoun, M, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 122 (2010), 985–992.
18. 18 Cleland, JG, McMurray, JJ, Kjekshus, J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54 (2009), 1850–1859.
19. 19 Rahimi, K, Bennett, D, Conrad, N, et al. Risk prediction in patients with heart failure: a systematic review and analysis. JACC Heart Fail 2 (2014), 440–446.
20. 20 Cleland, J, Freemantle, N, Ghio, S, et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol 52 (2008), 438–445.
21. 21 Shave, R, Baggish, A, George, K, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol 56 (2010), 169–176.
22. 22 Klinkenberg, LJ, van Dijk, JW, Tan, FE, van Loon, LJ, van Dieijen-Visser, MP, Meex, SJ, Circulating cardiac troponin T exhibits a diurnal rhythm. J Am Coll Cardiol 63 (2014), 1788–1795.
23. 23 Waldenstrom, A, Ronquist, G, Role of exosomes in myocardial remodeling. Circ Res 114 (2014), 315–324.